<DOC>
	<DOCNO>NCT00138632</DOCNO>
	<brief_summary>This study evaluate tolerability safety 3 month treatment PTK787 tablet give daily . It also explore efficacy compound patient wet age-related macular edema . In Cohort 1 verteporfin/PDT active control . The protocol amend reflect current standard care AMD . As result , ranibizumab active control Cohort 2 .</brief_summary>
	<brief_title>Safety Efficacy Oral PTK787 Patients With Subfoveal Choroidal Neovascularization Secondary Age-Related Macular Degeneration ( AMD )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Vatalanib</mesh_term>
	<criteria>Inclusion criterion Male ≥ 65 year old female ≥ 50 year old , age related macular degeneration Patients subfoveal choroidal neovascularization secondary AMD Exclusion criterion Eye disease may result visual loss study Uncontrolled high blood pressure , despite chronic stable treatment : systolic ≥ 140 mmHg , Diastolic ≥ 90 mmHg Chronic therapy topical , local systemic corticosteroid . Use investigational drug within 30 day Pregnant nursing ( lactate ) woman . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Wet Age-related macular degeneration</keyword>
	<keyword>PTK787</keyword>
</DOC>